Articles From: Northern Oil and Gas, Inc. Announces 2014 Second Quarter Results and Increases 2014 Production Guidance to Oramed Pharmaceuticals Reports Last Patient Out in Phase IIa Trial for ORMD-0801 in Type 1 Diabetes


ANCHORAGE, Alaska, Aug.
Sign-up for Northrim BanCorp to Acquire Residential Mortgage, LLC for $29.8 Million investment picks
ROLLING MEADOWS, Ill.
Sign-up for Northrop Grumman Awards Engineering Scholarships to Two Rolling Meadows Area Students investment picks
GAITHERSBURG, Md., Aug.
Sign-up for Novavax to Present at the Wedbush Securities Life Sciences Management Access Conference investment picks
NRG Energy, Inc. (NYSE:NRG) today reported second quarter 2014 Adjusted EBITDA of $671 million with Wholesale contributing $389 million, Retail contributing $173 million and NRG Yield contributing $109 million.
Sign-up for NRG Energy, Inc. Reports Second Quarter Results; Completed First NRG Yield Drop Down and Announces Formation of NRG Home and NRG Renew investment picks
NRG Yield, Inc. (NYSE:NYLD) today reported second quarter 2014 Adjusted EBITDA of $109 million.
Sign-up for NRG Yield, Inc. Reports Second Quarter 2014 Financial Results, Completes First ROFO Acquisition, Closes Green Bond and Equity Offerings, and Raises Quarterly Dividend by 4.3% investment picks
2014/8/7
Rapidly evolving laws and enforcement have opened major opportunities in the U.S. cannabis sector for start-ups and small businesses.
Sign-up for NTRR: Small Businesses Seize Big Opportunities in Cannabis Industry investment picks
NTT Communications Corporation (NTT Com), the global data and IP services arm of telecom leader NTT (NYSE: NTT), and RagingWire Data Centers (RagingWire), the premier data center provider in the United States and an NTT Communications group company, today announced that NTT Com has expanded its Tier-1 Global IP Network into RagingWire’s data center facilities in Ashburn, Virginia, and Sacramento, California.
Sign-up for NTT Communications Expands Global IP Network Footprint with RagingWire in Ashburn, Virginia and Northern California investment picks
2014/8/7
http://media.marketwire.com/attachments/201401/70716_nutroganicslogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1136206&ProfileId=051205&sourceType=1 BETHESDA, MD --
Sign-up for Nutroganics, Inc. (NUTT) Announces 2014 Second Quarter Results and Guidance for Second Half investment picks
Nuverra Environmental Solutions (NYSE:NES) (“Nuverra” or “the Company”), a leading provider of full-cycle environmental solutions to the energy and industrial end-markets, today announced financial results for its second quarter and six months ended June 30, 2014.
Sign-up for Nuverra Environmental Solutions Reports Second Quarter 2014 Results investment picks
http://media.marketwire.com/attachments/201210/52110_NVLogo2D.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1136175&ProfileId=051205&sourceType=1 SANTA CLARA, CA --
Sign-up for NVIDIA Financial Results for Second Quarter Fiscal 2015 investment picks
--Revenue Increases to $74.1 million, up 13% from Q2'13 --Home Revenue Increases to $38.5 million, up 18% from Q2'13 --Company Expects to Top 15% Annual Growth Target for Home in 2014 --Company Increases Full-Year 2014 Revenue Guidance to be between $290 and $293 million LAWRENCE, Mass.
Sign-up for NxStage Reports Record Second Quarter 2014 Financial Results And Increases Full-Year Revenue Guidance investment picks
2014/8/7
ST. AUGUSTINE, Fla.
Sign-up for O2 Secure Wireless, Inc. And LOOKHU, Inc. Announce A Strategic Alliance And Program Licensing Agreement investment picks
Net loss of $70,000, reduced $1.6 million from same period last year Oculus owns two million shares of Ruthigen (Nasdaq:RTGN) Net worth of $13.4 million, up $10.8 million from June 30, 2013 Cash position of $5 million with $64,000 in debt Conference Call Begins at 4:30 p.m. (EDT) Today PETALUMA, Calif., Aug.
Sign-up for Oculus Innovative Sciences Reports Revenues of $3.4 Million and Net Loss of $70,000 for First Quarter of Fiscal 2015 investment picks
Enable partnership drives higher earnings OKLAHOMA CITY , Aug.
Sign-up for OGE Energy Corp. reports second quarter results investment picks
Second-Quarter 2014 Sales and Earnings Improve Sharply From Year-Ago Levels CLEVELAND, Aug.
Sign-up for Olympic Steel Reports Record Net Sales investment picks
Omnicell OmniRx Earns Top KLAS Award for Automated Dispensing Systems for Ninth Consecutive Year MOUNTAIN VIEW, Calif.
Sign-up for Omnicell Repeats as Top Overall Pharmacy Vendor in 2014 KLAS Pharmacy Equipment Rankings investment picks
2014/8/7
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2014 Conference call to be held on Thursday, August 7, 2014 at 4:30 p.m. Eastern Time Canada NewsWire BOTHELL, Wash.
Sign-up for OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2014 investment picks
2014/8/7
Conference call to be held on Thursday, August 7, 2014 at 4:30 p.m. Eastern Time BOTHELL, Wash.
Sign-up for OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2014 investment picks
2014/8/7
CALGARY , Aug.
Sign-up for Oncolytics Biotech® Inc. Announces Second Quarter 2014 Results investment picks
REDWOOD CITY, Calif., Aug.
Sign-up for OncoMed Pharmaceuticals Announces Second Quarter 2014 Financial Results investment picks
OPKO Health, Inc. (NYSE: OPK), announced the submission of an Investigational New Drug (IND) Application to the United States (U.S.) Food and Drug Administration (FDA) under which Rayaldee ™ will begin clinical evaluation as an adjunctive therapy for the prevention of skeletal-related events (SREs) in patients with bone metastases undergoing anti-resorptive therapy.
Sign-up for OPKO Submits IND for Rayaldee™ as Adjunctive Cancer Therapy investment picks
OPKO Health, Inc. (NYSE: OPK ) will announce top line data from the first of two identical pivotal Phase 3 clinical trials for RAYALDEE™ and its second-quarter 2014 financial results on Monday, August 11, 2014, after the market closes.
Sign-up for OPKO to Announce Top Line RAYALDEE Results and Second Quarter 2014 Financial Results on August 11, 2014 investment picks
FREMONT, Calif., Aug.
Sign-up for Oplink Reports Fourth Quarter and Fiscal Year 2014 Financial Results investment picks
CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its oral presentation given by Sant P.
Sign-up for Oral Presentation of CytRx’s Aldoxorubicin Phase 2b Clinical Trial in Soft Tissue Sarcoma Highlighted in The Lancet Oncology investment picks
-Results published in Science show small molecule SMN2 splicing modifiers to be effective in SMA mouse models- SOUTH PLAINFIELD, N.J. , Aug.
Sign-up for Orally Delivered Compounds, Which Selectively Modify RNA Splicing Prevent Deficits In Mouse Models Of Spinal Muscular Atrophy investment picks
Top-Line Data Expected in Q4 of 2014 JERUSALEM , August 7, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) ( http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today reports that the last patient has completed treatment in its Phase IIa clinical trial of ORMD-0801, the Company's proprietary oral insulin capsule, to treat type 1 diabetes, and top-line data is expected to be reported in the fourth quarter of 2014.
Sign-up for Oramed Pharmaceuticals Reports Last Patient Out in Phase IIa Trial for ORMD-0801 in Type 1 Diabetes investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Northern Oil and Gas, Inc. Announces 2014 Second Quarter Results and Increases 2014 Production Guidance to Oramed Pharmaceuticals Reports Last Patient Out in Phase IIa Trial for ORMD-0801 in Type 1 Diabetes
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices